Extended letrozole improves disease-free survival in hormone receptor-positive breast cancer: 15-year results

Share :
Published: 24 Oct 2026
Views: 197
Rating:
Save
Prof Eleftherios Mamounas - AdventHealth Cancer Institute, Orlando, USA

Prof Eleftherios Mamounas talks to ecancer at ESMO 2026 about the final analysis of the phase III NSABP B-42 trial, evaluating extended adjuvant letrozole in postmenopausal women with hormone receptor-positive breast cancer.

The study randomised 3,966 patients who had completed five years of endocrine therapy to receive an additional five years of letrozole or placebo.

After a median follow-up of 15.9 years, extended letrozole significantly improved disease-free survival (61.6% versus 56.5%; HR 0.85), reduced distant recurrence (6.9% versus 9.7%) and improved breast cancer-free interval.

However, no significant overall survival benefit was observed (HR 0.92).

The findings demonstrate a sustained benefit from extended letrozole therapy, with no attenuation of treatment effect between 10 and 15 years of follow-up.
 

This information is intended for health care professionals only. The information is not intended for US health care professionals.

Related Videos

Giredestrant plus palbociclib shows limited benefit in ER-positive, HER2-negative metastatic breast cancer

Dr Mabel Mardones - Rocky Mountain Cancer Centers, Denver, USA
Giredestrant plus palbociclib shows limited benefit in ER-positive, HER2-negative metastatic breast cancer ( Dr Mabel Mardones - Rocky Mountain Cancer Centers, Denver, USA )
10 Jun 2026

Sacituzumab govitecan improves PFS across Trop-2, BRCA, and HER2 metastatic triple-negative breast cancer

Dr Sara Tolaney - Dana-Farber Cancer Institute, Boston, USA
Sacituzumab govitecan improves PFS across Trop-2, BRCA, and HER2 metastatic triple-negative breast cancer ( Dr Sara Tolaney - Dana-Farber Cancer Institute, Boston, USA )
9 Jun 2026

Sacituzumab govitecan plus pembrolizumab improves PFS across biomarker subgroups in metastatic triple-negative breast cancer

Dr Sara Tolaney - Dana-Farber Cancer Institute, Boston, USA
Sacituzumab govitecan plus pembrolizumab improves PFS across biomarker subgroups in metastatic triple-negative breast cancer ( Dr Sara Tolaney - Dana-Farber Cancer Institute, Boston, USA )
9 Jun 2026

FX-909 shows tumour regression in PPARG-high advanced urothelial carcinoma

Dr Matthew Galsky - Icahn School of Medicine at Mount Sinai, New York, USA
FX-909 shows tumour regression in PPARG-high advanced urothelial carcinoma ( Dr Matthew Galsky - Icahn School of Medicine at Mount Sinai, New York, USA )
6 Mar 2026

Omitting sentinel lymph node biopsy is safe in early HR-positive, HER2-negative breast cancer after 5 years

Prof Marjolein Smidt - Maastricht University Medical Center, Maastricht, Netherlands
Omitting sentinel lymph node biopsy is safe in early HR-positive, HER2-negative breast cancer after 5 years ( Prof Marjolein Smidt - Maastricht University Medical Center, Maastricht, Netherlands )
16 Dec 2025

Sacituzumab govitecan improves PFS in first-line metastatic TNBC patients unable to receive PD-(L)1 inhibitors

Dr Javier C Cortés - Hospital Ruber Internacional, Madrid Spain
Sacituzumab govitecan improves PFS in first-line metastatic TNBC patients unable to receive PD-(L)1 inhibitors ( Dr Javier C Cortés - Hospital Ruber Internacional, Madrid Spain )
20 Oct 2025

177Lu-PSMA-617 in metastatic castration-resistant prostate cancer shows higher PSA response with lower toxicity

Dr Kim Nguyen Chi - BC Cancer, British Columbia, Canada
177Lu-PSMA-617 in metastatic castration-resistant prostate cancer shows higher PSA response with lower toxicity ( Dr Kim Nguyen Chi - BC Cancer, British Columbia, Canada )
20 Oct 2025

Targeted therapies associated with increased risk for and incidence of thrombosis in the treatment of breast cancer

Dr James Martin - Cleveland Clinic, Cleveland, USA
Targeted therapies associated with increased risk for and incidence of thrombosis in the treatment of breast cancer ( Dr James Martin - Cleveland Clinic, Cleveland, USA )
20 Dec 2024

HER3-DXd demonstrates similar efficacy compared to multi-agent chemotherapy in high-risk HR-positive/HER2-negative eBC

Dr Mafalda Oliveira - Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain
HER3-DXd demonstrates similar efficacy compared to multi-agent chemotherapy in high-risk HR-positive/HER2-negative eBC ( Dr Mafalda Oliveira - Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain )
19 Dec 2024